

## IOANNA ANDREADOU

### **Professional address:**

Dept. of Pharmaceutical Chemistry  
School of Pharmacy, University of Athens  
Panepistimiopolis, 15771 Zografou  
Tel: (30) 2107274827 Fax: (30) 2107274747  
email: jandread@pharm.uoa.gr

### **Home address:**

6-8 Menemenis Str  
16122 Kesariani, Athens  
Tel: (30) 2107290879

**Date of birth:** 11 November 1965

**Place of birth:** Athens

## **EDUCATION**

- 1988 Degree in Pharmacy, Aristotle's University of Thessaloniki.
- 1994 PhD in Medicinal Chemistry Aristotle's University of Thessaloniki.
- 1994-1996 Post-doctoral training (Leiden Amsterdam Center for Drug Research, Vrije Universiteit Amsterdam, Div. of Molecular Toxicology).
- PhD Thesis: Synthesis of novel anti-inflammatory compounds with basic character: correlation of structural characteristics with activity upon free radicals, drug metabolism and inflammation.
- PostDoc Thesis: Mechanism based design of novel Se-substituted selenocysteine derivatives as potential kidney selective prodrugs.

## **LANGUAGES**

ENGLISH (Proficiency –Central London College), May 1982.

SPANISH Basic knowledge

## **FELLOWSHIPS**

- 1988-1991 State Scholarship Foundation, Athens (Greece)
- 1994 Human Capital and Mobility (Leiden, the Netherlands)
- 1995 European Science Foundation (Strasbourg France)
- 2009 Hellenic Society of Cardiology (Greece) Υποτροφία για μετεκπαίδευση στο THE HATTER CARDIOVASCULAR INSTITUTE, Research Department of Cardiovascular Medicine, Division of Medicine, University College London Hospital & Medical School- Φεβρουάριος-Μάρτιος 2009.

## RESEARCH AND PROFESSIONAL CARRER

<b>2016-</b>	Associate Prof. of Pharmacology, Pharmaceutical Chemistry Division, School of Pharmacy, Univ. of Athens.
<b>2011-2016</b>	Assistant Prof. of Pharmacology, Pharmaceutical Chemistry Division, School of Pharmacy, Univ. of Athens.
<b>2006-2011</b>	Lecturer of Pharmacology, Pharmaceutical Chemistry Division, School of Pharmacy, Univ. of Athens.
<b>2003-2006</b>	Teaching Associate, School of Pharmacy, Univ. of Athens
<b>2005-today</b>	Research fellow, B' University Dept. of Cardiology, Medical School, Attikon General Hospital, Athens
<b>1998-2005</b>	Clinical Reasearch Accosiate Manager INTERACT (International Academic Coordination of Trials)
<b>1996-1998</b>	ELPEN Pharmaceutical Company: R & D Department

### CLINICAL TRIALS

**1998-2005** Clinical Reasearch Accosiate Manager INTERACT (International Academic Coordination of Trials):

**EUROPA 1/1/1998 –30/12/2003:** EUropean trial on Reduction Of cardiac events with Perindopril in stable coronary Artery (EUROPA) disease.

**PERFECT:** Sub-study: PERindopril-Function of the Endothelium in Coronary Artery Disease Trial

**PERSPECTIVE:** Perindopril's prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation.

**SOTI:** The Spinal Osteoporosis Therapeutic Intervention (SOTI): Strontium ranelate: short- and long-term benefits for post-menopausal women with osteoporosis.

**TROPOS:** Strontium Ranelate Reduces the Risk of Nonvertebral Fractures in Postmenopausal Women with Osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) Study.

**PREAMI 5/2000 – 12/2003:** *Perindopril and Remodelling in Elderly with Acute Myocardial Infarction.*

**3/2000-2005: CARISA:** *A double-blind, randomized, stratified, placebo-controlled, parallel study of Ranolazine SR at doses of 750 mg twice a day and 1000 mg twice a day in combination with other anti-anginal medications in patients with chronic stable angina pectoris.*

### EXPERT EVALUATOR OF EUROPEAN RESEARCH GRANDS

1 .Executive Board of the Austrian Science Fund I, FWF, Project number: P2289-B18.

2. Expert Evaluator of H2020 Marie Skłodowska-Curie Initial Training Networks (ITN), February-March 2015.

3. Expert Evaluator of Marie Skłodowska-Curie Individual Fellowships H2020-MSCA-IF-2015, October-November 2015.

4. Expert Evaluator of H2020 Marie Skłodowska-Curie Initial Training Networks (ITN), February-March 2016.

5. Expert Evaluator of Marie Skłodowska-Curie Individual Fellowships H2020-MSCA-IF-2015, October-November 2016.

## **LIST OF RESEARCH PROJECTS**

1. “Chemical analyses and bioactivities of Greek varieties of olive trees and Greek virgin oil”  
Budget: 158.474€  
PENED  
Participant  
2002-2005
2. “Development of an economically viable process for the integrated management of winemaking industry waste; production of high added value natural products”  
Budget: 1.316.423€  
LIFE 03 ENV/GR/000223 DIONYSOS.  
Participant  
2003-2006  
**AWARD TOP-5 BEST of the BEST Life projects in EU for 2007-2008**
3. “Effect of phytosterols of Chios Masrtic gum in atheromatosis”  
Budget: 114.000€  
PENED  
Participant  
2003-2006
4. “Development of novel molecules, analogues of nicorandil and adenosine as ischemic preconditioning pharmacological triggers”  
Budget: 15000€  
Hellenic Society of Cardiology  
Scientific Responsible  
2007-2009
5. “Design and synthesis of novel molecules as pharmacological postconditioning triggers”  
Budget: 3000 €  
Hellenic Society of Cardiology  
Scientific Responsible  
2008-2010
6. “Effect of the olive oil constituent, oleuropein on chronic heart failure induced by adriamycin: investigation of the molecular mechanism”  
Budget: 8000 €  
Ministry of Health,  
Participant  
2009-2011
7. “Molecular mechanism investigation of remote postconditioning”  
Budget: 8000 €  
Ministry of Health  
Participant  
2009-2011
8. “The role of oxidative stress mechanisms on symptomatic carotid disease”  
Budget: 6000 €  
National Program «KAPODISTRAS»  
Scientific responsible  
2009-2011

9. "H<sub>2</sub>S, a new signaling molecule in cardiovascular system: Investigating the mechanism of action"  
Budget: 8000 €  
Hellenic Society of Cardiology  
Participant  
2009-2011
10. "Investigation of the antiatheromatic and cardioprotective activities of olive constituents, oleuropein and oleocanthal"  
Budget: 8000 €  
Hellenic Society of Cardiology  
Scientific Responsible  
2010-2012
11. Cost-Action FA0602-Bioactive Food Components, Mitochondrial Function and Health, Substituted member  
2007-2011
12. Cost-Action actions BM1005- Gasotransmitters: from basic science to therapeutic applications. Management Committee Member  
2011-15
13. "GSK3 $\beta$  as molecular target of myocardial infarct size reduction: study of its inhibition during reperfusion in vivo"  
Budget: 5000 €  
Hellenic Society of Cardiology  
Scientific Responsible  
2012-2014
14. Cost Action EU-ROS (2012-2016): The European Network on Oxidative Stress and Redox Biology Research, Management Committee Member. 2012-2016
15. "In vitro characterization and in vivo PK/PD study of the bioactive constituents of *Crocus sativus* (*Iridaceae*): investigation of antiatheromatic and cardioprotective effects and the development of per-os pharmaceutical formulation. (School of Pharmacy and UNIFARMA)"  
Budget: 240000 €  
PAVET:  
Participant  
2013-2015
16. "Exploitation of edible plants rich in sulfur and phenolic compounds in the development of drugs and food supplements. (School of Pharmacy, HEP, Galenica)"  
Budget: 310.093,80 €  
PAVET  
Participant  
2013-2015
17. "Study of a new mechanism of myocardial infarct size reduction of nitroglycerin"  
Budget: 5000 €  
Hellenic Society of Cardiology  
Scientific Responsible  
2015-2017

## **INVITED SPEAKER**

1. 4/11/1998: INTERACT, Paris, title: "Procedures of clinical trials"
2. 6/10/1999: INTERACT meeting of South Europe, Brescia, title: "Auditing, General Aspects"
3. 4/11/1999: INTERACT meeting of all Europe, Paris, title: "The Markers sub-study: Influence of perindopril on the markers of inflammation, coagulation and thrombosis"
4. 11/4/2000: Cardiology Clinic of Corinth Hospital, title: "Endothelial function and angiotensin-converting enzyme inhibitors".
5. 20/2/2003: Hellenic Society of Cardiology, title: "Novel antioxidant compounds with beneficial effect in ischemic myocardium".
6. 11/04/2003: Oral awards session, 3<sup>rd</sup> International Meeting 10<sup>th</sup> Anniversary of the Onassis Cardiac Surgery Center. Subject: "Infarct size limitation by a novel indole derivative with antioxidant and free radical scavenging properties".
7. 22/11/2003: Hellenic Cardiology Society, title: "Oxidative stress and cardiovascular disease", Nafplio.
8. 20/2/2004: Hellenic Cardiology Society, title: "New pharmacological interventions for ischemic preconditioning".
9. 17/06/2004: B' University Anesthesiology Clinic, title: "Oxidative stress and pathophysiological situations"
10. 9/10/2004: Hellenic Society of Free Radicals and Oxidative Stress, title: "The role of reactive oxygen species in myocardial protection".
11. 19/2/2005: Hellenic Cardiology Society, title: "The role of antioxidants in myocardial protection".
12. 27/6/2005: LIFE ENVIRONMENT (DIONYSOS), title: "Clinical evaluation of the effect of wine products in the endothelial function in patients with coronary artery disease".
13. 09/12/2005: 1<sup>st</sup> Hellenic Conference of Basic Medical Sciences, title: "Basic research in cardiology".
14. 16/02/2006: Hellenic Cardiology Society, title: "The role of vitamins in ischemic preconditioning".
15. 29/09/2006: Hellenic Society of Free Radicals and Oxidative Stress, title: "Cardioprotective activity of the olive constituent product, oleuropein".
16. 13/12/2006: Prefectoral self-government of East Attica, Spata, title: "Pharmacological exploitation on the effect of agricultural by-products in the cardiovascular system in patients with coronary artery disease".
17. 9/03/2007: Co-operative Association of wine products, Thessaloniki, title: "Pharmacological exploitation on the effect of Greek wine products in patients with coronary artery disease".
18. 31/05/2008: International Society for Heart Research, Athens, title: "Current Research in Greece: Heart failure and beyond".
19. 7-10/05/2009: 8<sup>th</sup> International Congress on Patient perspectives for the quality of life "Cardiovascular Risk", Cappadokis, Turkey, title: "Oxidative stress and myocardial infarct size".
20. 24/10/2009: Clinical seminar, Athens, title: "Mechanisms and pharmacological cardioprotective interventions in acute ischemia".
21. 19/02/2010: Hellenic Cardiology Society, title: "Inflammation and myocardial protection".

22. 11/03/2010: 6<sup>th</sup> Conference of Atherosclerosis, title: "Endogenous mechanisms of cardioprotection and atheromatosis".
23. 24/04/2010. 14<sup>th</sup> Hellenic Symposium on Medicinal Chemistry, title: "Novel therapeutic strategies for coronary heart disease based on the endogenous mechanisms of cardioprotection".
24. 11/06/2010: 7<sup>th</sup> Conference of Free Radicals and Oxidative Stress, title: "Pharmacological evaluation of antioxidants of Mediterranean diet in cardiovascular system".
25. 30/09/2010. Cost Action FA0602, Coimbra, Portugal, title: "Bioactive compounds of olive tree".
26. 19/02/2011. Hellenic Cardiology Society, title: "Investigation of the cellular mechanisms in remote ischemic conditioning".
27. 11/11/2011. National Research Foundation, "Structure- & Computer- Aided Design Workshop: Bioactive Molecules & Materials", title: "Novel targets as pharmacological tools for the development of new therapeutic strategies for the coronary heart disease".
28. 19/10/2012. Cost Action BM1005 2nd Workshop, Budapest, Hungary title: "Endogenous mechanisms of cardioprotection and atheromatosis: the role of NO".
29. 15.02/2013. Hellenic Cardiology Society, title: "Mechanism of the abrogation of the cardioprotective effect of ischemic postconditioning in atheromatosis".
30. 9/03/2013. Symposium on "Channels of cellular membranes in health and disease", Attikon Hospital, title: "Channels and mediators in myocardial conditioning".
31. 20/3/2013. BRFFA, "Introduction to translational cardiovascular research", title: "Oxidative stress and myocardial conditioning".
32. 12/4/2013 Cost Action BM1005 3<sup>rd</sup> Working Group Meeting, Smolenice, Slovakia, title: "Cardioprotective role of H<sub>2</sub>S".
33. 12/05/2013. International Workshop in Bioactive compounds from *Olea europaea*: Chemistry and Biology, title: "Cardioprotective properties of the olive constituent oleuropein".
34. 1/06/2013. 1<sup>st</sup> International Scientific Conference: "Cardiovascular biotechnology: from cell to man", title: "Myocardial conditioning: mechanisms and clinical applications".
35. 9/12/2013. Cost Action BM1203, Workgroup Meeting Madrid, title: "Endogenous mechanisms of cardioprotection and atheromatosis: the role of NO and nitrosative stress".
36. 12/03/2014. BRFFA, "Introduction to translational cardiovascular research", title: "Myocardial conditioning: Signal transduction".
37. 2/5/2014. Cost Action BM1005 4<sup>th</sup> Working Group Meeting, Messina, Italy, title: "Nitroglycerin as a postconditioning agent".
38. 24/5/2014. Hellenic Society of Biological Sciences, Ioannina, title: "Evaluation of new molecular targets based on the endogenous mechanisms of cardioprotection (preconditioning, postconditioning and remote conditioning)".
39. 19/9/2014. BRFFA, "Introduction to translational cardiovascular research", title: "Pre-peri-post conditioning".
40. 26/2/2015. Hellenic Cardiology Society, title: "H<sub>2</sub>S: a new signaling molecule in the cardiovascular system: its role in cardioprotection".
41. 2/5/2015. Cost Action BM1005 closing Action Conference, Athens, title: "Endothelial nitric oxide synthase activation in cardioprotection".

42. 14/5/2015. BRFFA, “Introduction to translational cardiovascular research”, title: “Pre-peri-post conditioning: Signal transduction”.

## **TEACHING ACTIVITIES**

1. Pharmacology I
2. Pharmacology II
3. Advanced Pharmacology, Master Sciences Degree in “Drug Design and Development”, specialization “Pharmacology”.
4. Clinical Pharmacology, Master Sciences Degree in Clinical Pharmacy”.
5. Pharmaceutical Analysis Laboratory training of 4th year students. Department of Pharmacy of Pharmacy, University of Athens.
6. Pharmacology, Master Sciences Degree in “Intensive Care Units and emergency nursing”, Medical School, University of Athens. «Μονάδες εντατικής θεραπείας και επείγουσα νοσηλευτική».
7. Pharmaceutical Technology Laboratory training of 4th year students. Department of Pharmacy, University of Athens, 2003-2004, 2004-2005.
8. Seminars for the education of medical practitioners (cardiologists) in the protocols of the clinical studies.
9. Laboratory training of molecular pharmacology, toxicology, minor programs of the 4<sup>th</sup> year students of Vrije University of Amsterdam, 1992-1994.
10. Pharmaceutical Chemistry Laboratory training, Department of Pharmacy, Aristotelis University of Thessaloniki, 1990-1993.

### ***Supervising PhD students***

1. “*Effect of oleuropein in doxorubicin-induced heart failure: study of the mechanism of action*”. K. Ioannidis, School of Pharmacy, University of Athens, 2013.
2. “*Role of nitric oxide and hydrogen sulfide in myocardial protection*”, S.I. Bibli, School of Pharmacy, University of Athens, Co-supervisor with Prof A. Papapetropoulos, 2016.
3. “*Investigation of novel molecules and drugs in in vivo models of cardiovascular diseases*”, P. Efentakis, School of Pharmacy, University of Athens, in progress.

### ***Member of the supervising committee of PhD students***

4. “*Exploitation of the role of oleuropein in lipid homeostasis and in myocardial ischemia/reperfusion injury: possible involvement of PPARs*”, F. Malliou, Department of Pharmacology, Medical School, University of Ioannina.
5. “*Production and functional role of hydrogen sulfide in cellular signaling*”, A. Pavlidou, School of Pharmacy, University of Athens.
6. “*Regulation of hydrogen sulfide metabolism*”, A. Katsouda, School of Pharmacy, University of Athens.
7. “*In vitro and in vivo studies for the development/evaluation pharmacological (PK/PD) active compounds*”, E. Christodoulou, School of Pharmacy, University of Athens.
8. “*Study of molecular mechanisms of postconditioning protection in target organs after kidney exclusion of abdominal aorta*”, D. Karageorgiadis, Department of Vascular Surgery, Medical School, University of Athens.

9. "Investigating the cardioprotective activity of hydrogen sulfide donors in experimental animals with comorbidities", A. Chatziathanasiou, Department of Pharmacology, Medical School, Demokriton University of Thrace.
10. "Investigation of remote ischemic conditioning: study of mechanism of action", E. Mastromanolis, Department of Cardiology, Medical School, University of Athens.

***Supervising Master students in "Clinical Pharmacy".***

1. "The inhibition of interleukin-1 activity from Anankira reduces apoptosis through nitro-oxidative stress reduction and improves myocardial function in patients with rheumatoid arthritis", P. Dasou. (Paper No 76).
2. "Study on the activity of different iron-chelating drugs in patients with  $\beta$ -thalassemia with left ventricular dysfunction", A. Matsa.
3. "Investigating the effect of functional electric stimulation on nitro-oxidative stress biomarkers in patients with chronic heart failure", D. Krampi.
4. "Investigating the effect of inhibition of interleukin-1 from anankira in mechanism of apoptosis, inflammation and nitro-oxidative stress in patients with acute myocardial infarction", Ch. Katseli. (Paper No 91).
5. "Investigating the effects of statins in atheromatic plaques stability in patients with carotid artery disease", D. Karageorgiadis.
6. "The effect of iron-chelating drugs in biomarkers of iron overload and nitro-oxidative stress in patients with hemosperinopathies", G. Voulgaris.
7. "Investigating the effect of biological therapies in patients with psoriasis in biomarkers of oxidative stress and inflammation", K. Gravanis. (Εργασία No 93).
8. "Effect and comparison of three different therapies for smoking cessation in nitro-oxidative stress biomarkers and in thiosulfate levels in smokers", N. Liarakos.
9. "Effect of the starting pharmaceutical medication in nitro-oxidative stress in patients with acute heart failure", V. Dede.

***Supervising Master students in Molecular Medicine.***

10. «Ablation of dysferlin gene ameliorates desmin deficient cardiomyopathy», E. Lekka.

***Supervising Master students in Pharmaceutical Analysis - Quality Control***

11. "Investigation of the mechanism of action and determination of the levels of olive constituent oleuropein in normal and in the atheromatic myocardium", M. Constantinou.
12. "The effect of pharmacological inhibition of b-adrenergic and muscarinic receptors in remote ischemic conditioning", S. Vasileiou.
13. "Pharmacological evaluation and determination of the levels of  $S_2O_3^{2-}$  (as hydrogen sulfide marker) released from novel adenine- $H_2S$  slow release donors designed as cardiopeotective agents", S. Toumpas.
14. "Determination of biomarkers and metabolites and the effect of levosimendan in doxorubicin- induced acute cardiomyopathy", A. Antipas.

***Master Theses of Clinical Pharmacy.***

1. "Study of the effect of the antagonists of I1b/IIIa receptor antagonists (tirofiban hydrochloride- vs eptifibatide) in biomarkers of inflammation and



- endothelium adhesion molecules in patients with unstable angina*", K. Mademli. (Paper No 43).
2. "Comparison of the effect of quinapril vs telmisartan vs placebo in biomarkers of oxidative stress, inflammation and in adhesion molecules in stable coronary artery disease patients", G. Ganatsios.
  3. "Effect of manitol in extensive hepatectomy", A. Teloudis. (Paper No 42).
  4. "Comparative study on the effect of levosimendan vs dobutamine in patients with advanced heart failure in biomarkers of oxidative stress and inflammation and BNP", M. Demopoulou. (Paper No 30).
  5. "Metabolomic analysis with <sup>1</sup>H-NMR in patients with congestive heart failure: comparison of levosimendan, dobutamine and placebo", M. Stasinopoulos.
  6. "The effect of levosimendan in nitro-oxidative stress in patients with congestive heart failure: comparison of the effect of levosimendan, dobutamine and placebo", A. Louka. (Paper No 47).
  7. "Effect of darbepoetin -A in nitro-oxidative stress biomarkers in patients with severe heart failure and anemia", K. Ioannidis. (Paper No 63).
  8. "Effect of sertraline in nitro-oxidative stress biomarkers in patients with chronic heart failure and depression", N. Antonellos. (Paper No 74).

#### **Master Theses in Pharmaceutical Analysis - Quality Control**

9. "Study of the effect of non-steroidal anti-inflammatory drugs in N-demethylation of aminopyrine", E. Spyropoulou. (Paper No 73).
10. "Determination of biomarkers and metabolites in myocardial tissue for the study of the effect of oleuropein in doxorubicin-induced acute cardiotoxicity", M. Papaefthimiou. (Papers No 45 and 62).

#### **Master Theses in Pharmaceutical Chemistry**

11. "Design of novel heterocycles based on the mechanism of ischemic preconditioning with cardioprotective activity", Th. Fotopoulou. (Paper No 49).

#### **Supervising Undergraduate Theses**

1. "Effect of acute administration of simvastatin in normal and cholesterol fed rabbits during ischemic preconditioning", D. Kouremeti.
2. "Investigating the effect of pharmacological inhibition of GSK3 $\beta$  in myocardial protection in anesthetized rabbits", D. Haratsi.
3. "Investigating the effect of pharmacological inhibition of PI3 and adenosine receptors in the signal transduction pathways during myocardial remote ischemic preconditioning", K.-Ch. Delli, D. Karageorgiadis.
4. "Investigating the effect of the antioxidant activity of N-2-mercaptopropionylglycine (MPG) in ischemic preconditioning", Ch. Katseli.
5. "Investigating the effect of NO donors in preconditioning of the myocardium", A. Georgakopoulos.
6. "Comparison of the effect of simvastatin and pravastatin in hyperlipidemic rabbits with and without ischemic preconditioning", K. Spyridaki.
7. "Induction of preconditioning with exogenous administration of hydrogen sulfide in anesthetized rabbits: investigation of the mechanism of action", S.I. Bibli.

8. "GSK3 $\beta$  as molecular target for infarct size reduction: investigation of its inhibition during reperfusion", N. Zisopoulos, A. Lazari.
9. "Investigation of the cardioprotective activity of selective agonists of adenosine receptors in anesthetized rabbits", A. Antipas.
10. "Study of the effect of oleuropein in anti-apoptotic mechanisms, energy metabolism and NO homeostasis during doxorubicin induced heart failure", S. Toumpas.
11. "Investigation of the molecular mechanism of nitroglycerine –induced pharmacological postconditioning", A. Kalatzi.
12. Investigation of the molecular mechanism of pharmacological postconditioning after administration of the purine analogue, MK118", S. Korisianos.
13. "Comparative study of molecular mechanisms of the endogenous cardioprotective mechanisms (preconditioning, postconditioning and chronic myoskeletal ischemia)", M. Mpavela, I. Oikonomou.
14. "Ranolazine induces preconditioning and postconditioning through activation of the RISK pathway", P. Efentakis.
15. "Investigation of the molecular mechanism of JAK/STAT pathway in myocardial infarct size during remote preconditioning", D.K. Kipourou, D. Xenou.
16. "Investigation of the inhibition of the transcriptional factor STAT5 in preconditioning", V. Dede, G. Marinos.
17. "Investigation of a new mechanism of action of the cardioprotective activity of nitroglycerine", A. Nakis, F. Tsouki.
18. "Investigating the mechanisms of action of statins in atheromatic plaque stability in patients undergone endarterectomy", F. Iliopoulos.
19. "Comparison of the cardioprotective activity of oleuropein and postconditioning in vivo", S. Fotaras.
20. "Exploitation of the cardioprotective activity of *Crocus sativus* in Apoe(-/-) mice", A. Rizakou.
21. "Exploitation of the role of hydrogen sulfide and CO enzymes in atheromatic plaque stability in patients undergone endarterectomy", P. Zampas.
22. "Exploitation of the ability of different inhibitors of GSK3 $\beta$  in the inhibition of mitochondrial transition pore permeability", P. Nikolaou.

## **MEMBER OF ORGANIZING SCIENTIFIC COMMITTEES OF CONFERENCES**

\_15 Greek and National Conferences

### **MEMBERSHIP OF SCIENTIFIC COMMITTEES**

1. **General Secretary** Hellenic Society of Basic and Clinical Pharmacology.
2. Member of the Administration Board of the Working Group of Basic and Translational Cardiology. (Hellenic Society of Cardiology).
3. 2010: European Cardiology Society, **Working Group: Cardiovascular Pharmacology**.
4. 2015: **ISHR (International Society for Heart Research)**.
5. 1998-2008: Membership of the Administration Board of the Hellenic Society of Pharmacoshemistry (Member of European Federation of Medicinal Chemistry, and Member of EUFEPS)

6. 1998: Hellenic Society of Free Radicals and Oxidative Stress (Member of International Society for Free Radical Research)
7. 1998: Hellenic Society of Pharmacists
8. 1/1998: Hellenic Society of Pharmaceutical Medicine (ELEFI)
9. 02/2000: Hellenic Pharmaceutical Society (EFE)

### Monographies

Synthesis of novel anti-inflammatory compounds with basic character: correlation of structural characteristics with activity upon free radicals, drug metabolism and inflammation. PhD Thesis, Thessaloniki, 1994.

### Reviewer in Scientific Journals

- Archiv der Pharmazie
- Basic & Clinical Pharmacol & Toxicol
- Biomedical and Environmental Sciences
- **British Journal of Pharmacology**
- **Circulation**
- Cardiovascular Drugs and Therapy
- **Cardiovascular Research**
- Cardiovascular Therapeutics
- Cell Biochemistry and Biophysics
- Drug Design, Development and Therapy
- **European Journal of Heart Failure**
- European Journal of Pharmacology
- Food and Chemical Toxicology
- **Free Radical Biology & Medicine**
- Hell J Cardiology
- Human Immunology
- International Journal of Endocrinology
- **International Journal of Cardiology**
- International Journal of Molecular Sciences
- **Journal of Leukocyte Biology**
- Journal of Molecular and Cellular Medicine
- **Journal of Nutrition**
- **Journal of Pharmacology Experimental Therapeutics**
- Journal of Pharmacy & Pharmacology
- Journal of Physiology and Biochemistry
- Life Sciences
- **Mediators of Inflammation**
- Molecules
- Natural Product Research
- **Nitric Oxide**
- Nutrition Research
- **Oxidative Medicine and Cellular Longevity**
- Pathophysiology
- **Pharmacological Research Top Reviewer Award for the year 2009**
- Physiology Journal

- PLOS ONE

### **Publications in Peer-reviewed journals**

**IF: Impact factor του SCI Journal Citation Report 2015 \*Corresponding Author**

**Citations: exclusion of self citations**

1. **I. Andreadou**, E. Rekka, D. Hadjipavlou-Litina, and P.N. Kourounakis. Antioxidant and free radical scavenging activity of some mono- or diamines synthesized as potential anti-inflammatory agents, in relation to their structure. **J. Biopharm. Sci.**, 2: 291-304, 1991. (Citations 4)
2. **I. Andreadou**, E. Rekka, V.J. Demopoulos, and P.N. Kourounakis. Effect of some novel ethylenediamine and ethanolamine derivatives on carrageenan induced inflammation: Correlation with antioxidant activity and structural characteristics. **Res. Commun. Chem. Pathol. Pharmacol.**, 78: 245-248, 1992. (IF: 0.419) (Citations 7)
3. P.N. Kourounakis, E. Rekka, V.J. Demopoulos, Ek. Tani, **I. Andreadou**, E. Alexandrou. Active oxygen species, free radicals and pathophysiologic conditions. The pharmacochemical approach. **Metal ions in Biology and Medicine**, 2: 265-268, John Libbey Pblsh. London Paris, 1992. (Citations 2)
4. **I. Andreadou**, E. Rekka, D. Hadjipavlou-Litina, P.N. Kourounakis. Correlation of the structure of novel mono- and diamine derivatives with their effect on drug metabolizing enzymes. **Med. Chem. Res.**, 3: 233-239, 1993. (IF: 1.436)
5. **I. Andreadou**, W.M.P.B. Menge, J.N.M. Commandeur, E.A. Worthington, N.P.E. Vermeulen. Synthesis of novel Se-substituted selenocysteine derivatives as potential kidney selective prodrugs. Structure-activity relationships with rat renal cysteine conjugate  $\beta$ -lyase. **J Med Chem**, 39: 2040-2046, 1996. (IF: 5.589) (Citations 126)
6. **I. Andreadou**, B. Van de Water, J.N.M. Commandeur, F.J. Nagelkerke, N.P.E. Vermeulen. Comparative cytotoxicity of novel Se-substituted selenocysteine conjugates in rat kidney proximal tubular cells. **Toxicol. Appl. Pharmacol.**, 141: 278-287, 1996. (IF: 3.847) (Citations 28)
7. **I. Andreadou**, E. Rekka, V.J. Demopoulos, G.J. Bijloo, P.N. Kourounakis. Synthesis, antioxidant and anti-inflammatory activity of novel substituted ethylenediamines and ethanolamines. A Preliminary QSAR study. **Arzneim. Fors./Drug Research**, 47: 643-647, 1997. (IF: 0.701) (Citations 22)
8. G. Kostopanagiotou, T. Pouriezis, K. Theodoraki, G. Kottis, **I. Andreadou**, V.Smyrniotis, L. Papadimitriou. Influence of ondansetron on thiopental hypnotic requirements. **J. Clinical Pharmacology**, 38: 825-829, 1998. (IF: 2.555) (Citations 2)
9. J.N.M. Commandeur, **I. Andreadou**, M. Rooseboom, M. Out, L. de Leur, E. Groot and N.P.E. Vermeulen: Bioactivation of selenocysteine Se-conjugates by

- a highly purified rat renal cysteine conjugate beta-lyase / glutamine transaminase K. **J. Pharmacol. Exp. Ther.**, 294: 753-761, 2000. (IF: 3.76) (Citations 50)
10. M. Rooseboom, N.P.E. Vermeulen, **I. Andreadou**, and J.N.M. Commandeur: Evaluation of kinetics of  $\beta$ -elimination reactions of selenocysteine Se-conjugates in human renal cytosol. Possible implications for the use as kidney selective prodrugs. **J. Pharmacol. Exp. Ther.**, 294: 762-769, 2000. (IF: 3.76) (Citations 30)
  11. **I. Andreadou**, A. Tsantili-Kakoulidou, Th. Siatra-Papastaikoudi: Significant antioxidant properties of indole containing derivatives of thiosemicarbazide and their cyclic 1,2,4- triazol analogs. **Res. Commun. Biochem. Cell and Mol. Biol.**, 4: 269-275, 2000. (Citations 6)
  12. **I. Andreadou**, A. Tasouli, E. Bofilis, M. Chrysselis, E. Rekka, A. Tsantili-Kakoulidou, E. K. Iliodromitis, T. Siatra, D. Th. Kremastinos: Antioxidant activity of novel indole derivatives and protection of the myocardial damage in rabbits. **Chem. Pharm. Bull.**, 50: 165-168, 2002. (IF: 1.228) (Citations 23)
  13. **I. Andreadou**, A. Papalois, J.K. Triantafillidis, M. Demonakou, M. Vidali, V. Govosdis, E. Anagnostakis, P.N. Kourounakis: Beneficial effect of a novel non-steroidal anti-inflammatory agent with basic character and antioxidant properties on experimental colitis in rats. **Eur. J. Pharmacol**, 441: 209-214, 2002. (IF: 2.73) (Citations 9)
  14. **I. Andreadou**, A. Tasouli, E. Iliodromitis, A. Tsantili-Kakoulidou, A. Papalois, T. Siatra, D. Th. Kremastinos: Reduction of myocardial infarct size in rabbits by a novel indole derivative with antioxidant and free radical scavenging properties. **Eur J Pharmacol**, 453: 271-277, 2002. (IF: 2.73) (Citations 30)
  15. **I. Andreadou**, E. Rekka, P.N. Kourounakis: Effect of novel anti-inflammatory ethanolamine derivatives with antioxidant properties on drug metabolizing enzymes. **Eur J Drug Metabol. Pharmacokin.**, 28: 7-10, 2003 (IF: 1.68) (Citations 4)
  16. R. Ferrari, G. Cicchitelli, E. Merli, **I. Andreadou**, G. Guardigli: Metabolic modulation and optimisation of energy consumption in heart failure. **Med. Clin. N. Amer.**, 87: 493-507, 2003. (IF: 2.333) (Citations 23)
  17. D. Poussios, **I. Andreadou\***, A. Papalois, E. Rekka, N. Gavalakis, K. Aroni, P.N. Kourounakis, C. Fotiadis, M. N Sechas: Protective effect of a novel antioxidant non-steroidal anti-inflammatory agent (IA) on intestinal viability after acute mesenteric ischemia and reperfusion. **Eur. J. Pharmacol.**, 465: 275-280, 2003. (IF: 2.73) (Citations 32)
  18. V. Panteleon, P. Marakos, N. Pouli, E. Mikros, **I. Andreadou**: Synthesis, conformational analysis and free radical scavenging activity of some new

- spiropyranoquinolinones. **Chem. Pharm. Bull.**, 51: 522-529, 2003. (IF: 1.228) (Citations 7)
19. V. Panteleon, P. Marakos, N. Pouli, E. Mikros, **I. Andreadou**: Interactions of a series of novel spiriopyrano coumarin derivatives with reactive oxygen species. **J. Pharm. Pharmacol.**, 55: 1029-1039, 2003. (IF: 2.363) (Citations 11)
  20. **I. Andreadou\***, A. Tsantili-Kakoulidou, E. Spyropoulou, T. Siatra: Reactions of indole derivatives with cardioprotective activity with reactive oxygen species. Comparison with melatonin. **Chem. Pharm. Bull.**, 51: 1128-1131, 2003. (IF: 1.228) (Citations 29)
  21. **I. Andreadou\***, D. Poussios A. Papalois, N. Gavalakis, K. Aroni, M. Gazouli, V. G., Gorgoulis, C. Fotiadis: Effect of U-74389G (21-Lazaroid) on intestinal recovery after acute mesenteric ischemia and reperfusion in rats. **In Vivo**, 17: 463-468, 2003. (IF: 0.832) (Citations 13)
  22. V. Smyrniotis, G. Kostopanagiotou, E. Lolis, K. Theothoraki, C. Farantos, **I. Andreadou**, G. Polymeneas, G. Giannatas, C. Contis: Effects of hepatovenous backflow on ischemic-reperfusion injuries in liver resections with the pringle maneuver. **J. Am. Coll. Surg.**, 197: 949-954, 2003. (IF: 4.257) (Citations 46)
  23. F. Sigala, G. Kostopanagiotou, **I. Andreadou\***, N. Kavatzas, E. Felekouras, P. Sigalas, E. Bastounis, E. Papalambros: Histological and lipid peroxidation changes after administration of 2-acetylaminofluorene in a rat liver injury model following selective periportal and pericentral damage. **Toxicology**, 196: 155-163, 2004. (IF: 3.817) (Citations 15)
  24. I. Leventis, **I. Andreadou\***, A. Papalois, D. Pousios, I. Sfiniadakis, D. Hadjipavlou-Litina, P.N. Kourounakis, V. G. Gorgoulis, C. Fotiadis. A novel antioxidant non-steroidal anti-inflammatory agent protects rat liver against ischemia-reperfusion injury. **In Vivo**, 18: 161-170, 2004. (IF: 0.832) (Citations 12)
  25. **I. Andreadou\***, E. Iliodromitis, E. Mikros, E. Bofilis, A. Zoga, M. Constantinou, A. Tsantili-Kakoulidou, and D. T. Kremastinos: Melatonin does not prevent the protection of ischemic preconditioning in vivo despite its antioxidant effect against oxidative stress. **Free Radic Biol Med**, 37: 500-510, 2004. (IF: 5.784) (Citations 37)
  26. E. Iliodromitis, A. Tasouli, **I. Andreadou**, E. Bofilis, A. Zoga, P. Cokkinos, and D. Th. Kremastinos: Intravenous atenolol and esmolol maintain the protective effect of ischemic preconditioning in vivo. **Eur. J. Pharmacol.**, 499: 163-169, 2004. (IF: 2.73) (Citations 15)
  27. F. Sigala, E. Papalambros A. Kotsinas, **I. Andreadou**, P. Sigalas, D. Kremastinos, I. Bastounis, VG Gorgoulis: Relationship between iNOS expression and aortic cell proliferation and apoptosis in an elastase-induced model of aorta aneurysm and the effect of W1400 administration. **Surgery**, 137: 447-456, 2005. (IF: 3.309) (Citations 15)

28. E. Karatzis, J. Lekakis, C. Papamichael, **I. Andreadou**, A. Cimponeriu, K. Aznaouridis, Th. Papaionannou, A. Protogerou, and M. Mavrikakis: Rapid effect of pravastatin on endothelial function and lipid peroxidation in unstable angina. **Int. J. Cardiol.**, 101: 65-70, 2005. (IF: 4.638) (Citations 48)
29. C. Vlachopoulos, K. Aznaouridis, N. Alexopoulos, E. Economou, **I. Andreadou**, C. Stefanadis. Effect of dark chocolate on arterial function in healthy individuals. **Am. J. Hypertens.**, 18(6): 785-791, 2005. (IF: 3.182) (Citations 155)
30. C. Avgeropoulou, **I. Andreadou\***, S. Markantonis-Kyroudis, M. Demopoulou, P. Missovoulos, A. Androulakis, I. Kallikazaros: The Ca<sup>2+</sup>-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine. **Eur J Heart Fail**, 7:882-887, 2005. (IF: 5.135) (Citations 96)
31. J. Lekakis, L. Rallidis, **I. Andreadou**, G. Vamvakou, G. Kazantzoglou, P. Magiatis, A. Skaltsounis, D. Kremastinos. Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease. **Eur J Cardiovasc Prev Rehabil**, 12: 596-600, 2005 (IF: 3.691) (Citations 141)
32. G., Kostopanagiotou, A. Pandazi, **I. Andreadou**, A. Doufas, I. Chondroudaki, Th. Kotsis, D. Rizos, C. Costopanagiotou and V. Smyrniotis: Effects of dopexamine on lipid peroxidation during aortic surgery in pigs: Comparison with dopamine. **Eur J Vasc Endovasc Surg**, 30: 648-653, 2005 (IF: 2.912) (Citations 1)
33. J. Lekakis, G. Vamvakou, **I. Andreadou**, G. Ganiatsos, E. Karatzis, Th. Papaioannou, I. Ikonomidis, Ch. Papamichael, M. Mavrikakis: Divergent effects of rofecoxib on endothelial function and inflammation in acute coronary syndrome syndromes. **Int J Cardiol**, 112: 359, 366, 2006. (IF: 4.638) (Citations 11)
34. E.K. Iliodromitis\*, A. Zoga, A. Vrettou, **I. Andreadou\***, I. A. Paraskevaidis, L. Kaklamanis, D. Th. Kremastinos: The effectiveness of postconditioning and preconditioning on infarct size in hypercholesterolemic and normal anesthetized rabbits. **Atherosclerosis**, 188:356-362, 2006. (IF: 3.942) (Citations 120)
35. F. Sigala, S. Theocharis, K. Sigalas, S. Markantonis-Kyroudis, E. Papalabros, A. Triantafyllou, G. Kostopanagiotou, **I. Andreadou\***: Therapeutic effect of melatonin in an experimental model of liver injury and regeneration. **J Pineal Research**, 40: 270-279, 2006. (IF: 9.314) (Citations 33)
36. G. Kostopanagiotou, S. Markantonis, N. Arkadopoulos, **I. Andreadou**, G. Charalambidis, J. Chondroudaki, C. Costopanagiotou, V. Smyrniotis: The effect of acutely induced hepatic failure on remifentanil and fentanyl blood

- levels in a pig model. **Eur J Anesthesiol**, 23: 598-604, 2006. (IF: 3.634) (Citations 8)
37. C. Vlachopoulos, N. Alexopoulos, I. Dima, K. Aznaouridis, **I. Andreadou**, Ch. Stefanadis: Acute effect of black and green tea on aortic stiffness and wave reflections. **J Am Coll Nutr**, 25: 216-223, 2006. (IF: 2.245) (Citations 39)
38. E. Sbarouni, E. Iliodromitis, A. Zoga, G. Vlachou, **I. Andreadou**, D. Kremastinos: The effect of phytoestrogen genistein on myocardial protection and on oxidative stress. **Cardiovasc Drugs Ther**, 20: 253-258, 2006. (IF: 3.189) (Citations 15)
39. **I. Andreadou\***, E. K. Iliodromitis, E. Mikros, M. Constantinou, A. Agalias, P. Magiatis, E. Kamber, A. L. Skaltsounis, A. Tsantili-Kakoulidou, D. Th. Kremastinos: The olive constituent oleuropein exhibits anti-ischemic, anti-oxidative and hypolipidemic effects in anesthetized rabbits. **J Nutr**, 136: 2213-2219, 2006. (IF: 3.74) (Citations 160)
40. **I. Andreadou\***, E. K. Iliodromitis, K. Tsovolas, I. K. Aggeli, A. Zoga, C. Gaitanaki, S. Markantonis, I. Beis, D. Th. Kremastinos: Acute administration of Vitamin E triggers preconditioning via KATP channels and cyclic-GMP without inhibiting lipid peroxidation. **Free Radic Biol Med**, 41: 1092-1099, 2006. (IF: 5.784) (Citations 26)
41. E. Karatzis, I. Ikonomidis, G. Vamvakou, Th. G. Papaioannou, A. D. Protogerou, **I. Andreadou**, P. Voidonikola, K. Karatzi, C. Papamichael, J. Lekakis. Long-term prognostic role of flow-mediated dilatation of the brachial artery after acute coronary syndromes without ST elevation. **Am J Cardiol**, 98: 1424-1428, 2006. (IF: 3.154) (Citations 90)
42. G. Kostopanagiotou, A. Pandazi, **I. Andreadou**, S. Kyroudi, D. Niokou, A. Teloudis, C. Costopanagiotou, N. Arkadopoulos, V. Smyrniotis: Effects of mannitol in the prevention of lipid peroxidation during liver resection with hepatic vascular exclusion. **J Clin Anesthesia**, 18: 570-574, 2006. (IF: 1.284) (Citations 22)
43. E.K Iliodromitis, **I. Andreadou**, S. Markantonis-Kyroudis, K. Mademli, P.Georgiadou, S. Kyrzopoulos, and D.T. Kremastinos: The Iib/IIIa glycoprotein inhibitor tirofiban improves oxidative stress and endothelial function in hospitalized patients with unstable angina. **Thrombosis Res**, 119: 167-174, 2007. (IF: 2.32) (Citations 21).
44. M. A. Constantinou, A. Tsantili-Kakoulidou, **I. Andreadou**, E. K. Iliodromitis, D. T. Kremastinos, E. Mikros. Application of NMR-based metabonomics to investigate the complexity emerged during ischemia-reperfusion in rabbits. Effect of preconditioning and exogenous intervention. **Eur J Pharm Sci**, 30: 303-314, 2007. (IF: 3.773) (Citations 23)
45. **I. Andreadou\***, F. Sigala, E. K. Iliodromitis, M. Papaefthimiou, C. Sigalas, N. Aligiannis, P. Savvari, V. Gorgoulis, E. Papalabros, D. Th. Kremastinos. Acute



- doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress. **J Mol Cell Cardiol**, 42: 549-558, 2007. (IF: 4.874) (Citations 139)
46. E. Papalabros, F. Sigala, S. Georgopoulos, KI Paraskevas, **I. Andreadou**, X. Menekakos, P. Sigalas, AL Papalambros, G. Vourliotakis, A. Giannopoulos, C. Bakoyannis, E. Bastounis. Malondialdehyde as an indicator of oxidative stress during abdominal aortic aneurysm repair. **Angiology**, 58: 477-482, 2007. (IF: 2.931) (Citations 25)
47. J. T. Parissis<sup>&</sup>, **I. Andreadou**<sup>&\*</sup>, S. L. Markantonis, V. Bistola, A. Louka, A. Pyriochou, I. Paraskevaidis, G. Filippatos, E. K. Iliodromitis, D. Th. Kremastinos. Effects of *Levosimendan* on Circulating Markers of Oxidative and Nitrosative Stress in Patients with Advanced Heart Failure. **Atherosclerosis**, 195:e210-215, 2007. (IF: 3.942) (Citations 46)
48. T. Fotopoulou, E. K. Iliodromitis, M. Koufaki, A. Tsotinis, A. Zoga, V. Gizas, A. Pyriochou, A. Papapetropoulos, **I. Andreadou**<sup>\*</sup>, D. Th. Kremastinos. Design and synthesis of nitroxy esters of aromatic heterocyclic compounds as pharmacological preconditioning agents. **Biorg Med Chem**, 16(8):4523-31, 2008 (IF: 2.923) (Citations 5)
49. G. Kostopanagiotou, E. Avgerinos, C. Costopanagiotou, N. Arkadopoulos, **I. Andreadou**, K. Diamantopoulou, M. Lekka, V. Smyrniotis, G. Nakos. Acute lung injury in a rat model of intestinal ischemia-reperfusion: the potential time dependent role of phospholipases A2. **J Surg Res**, 147: 108-116, 2008 (IF: 2.198) (Citations 29)
50. K. Tsovolas, E. K. Iliodromitis, **I. Andreadou**<sup>\*</sup>, A. Zoga, M. Demopoulou, K. E. Iliodromitis, S. L. Markantonis, D. Th. Kremastinos. Acute administration of Vitamin C abrogates protection from ischemic preconditioning in rabbits. **Pharmacol Res**, 57: 283-289, 2008 (IF: 4.816) (Citations 17)
51. C. Farantos, N. Arkadopoulos, K. Theodoraki, G. Kostopanagiotou, K. Katis, K. Tzavara, **I. Andreadou**, K. Dimopoulou, E. Hatzoudi, T. Sidiropoulou, I. Skalkidis, A. Paphiti, V. Smyrniotis. Effect of the portacaval shunt on reperfusion injury after 65% hepatectomy in pigs. **Eur Surg Res**, 40:347-353, 2008. (IF: 1.154) (Citations 7)
52. **I. Andreadou**<sup>\*</sup>, E. K. Iliodromitis, M. Koufaki, D. Th. Kremastinos. Pharmacological pre- and post- conditioning agents: reperfusion-injury of the heart revisited. **Mini Rev Med Chem**, 8: 952-959, 2008. (IF: 2.841) (Citations 40)
53. I. Ikonmidis, J.P. Lekakis, M. Nikolaou, I. Paraskevaidis, **I. Andreadou**, T. Kaplanoglou, P. Katsibri, G. Skarantavos, P.N. Soukakos, D. Th. Kremastinos. Inhibition of interleukin-1 by Anankira improves vascular and left ventricular function in patients with rheumatoid arthritis. **Circulation**, 117:2662-2269, 2008, (IF: 17.047) (Citations 140)

54. N. Arkadopoulou, D. Vlachakos, G. Kostopanagiotou, D. Panagopoulos, E. Karvouni, C. Routsis, K. Kalimeris, **I. Andreadou**, E. Kouskouni, V. Smyrniotis. Iron Chelation Attenuates Intracranial Pressure and Improves Survival in a Swine Model of Acute Liver Failure. **Liver Transplantation**, 14: 1116-1124, 2008. (IF: 3.951) (Citations 11)
55. P. Georgiadou, E.K.Iliodromitis, M. Mavroidis, F. Kolokathis, **I. Andreadou**, S.Psarras, Y. Capetanaki, H. Boudoulas, D.Th. Kremastinos. Relationship between plasma osteopontin and oxidative stress in patients with coronary artery disease. **Expert Opinion on Therapeutic Targets**, 12: 917-920, 2008. (IF: 4.798) (Citations 20)
56. J. T. Parissis, **I. Andreadou**, V. Bistola, I. Paraskevaïdis, G. Filippatos, D. T. Kremastinos. Novel biologic mechanisms of levosimendan and their effects on the failing heart. **Expert Opin Investig Drugs**, 17: 1143-1150, 2008. (IF: 4.408) (Citations 35)
57. D. Leftheriotis, K. Fountoulaki, P. Flevari, J. Parissis, F. Panou, **I. Andreadou**, K. Venetsanou, E. K. Iliodromitis, D. Th. Kremastinos. The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. **Int J Cardiol**, 135: 361-369, 2009. (IF: 4.638) (Citations 55)
58. V. Panteleon, I.K. Kostakis, P. Marakos, N. Pouli, **I. Andreadou**. Synthesis and Free Radical Scavenging Activity of Some New Spiropyranocoumarins. **Bioorg Med Chem Lett**, 18: 5781-4, 2008. (IF: 2.486) (Citations 25)
59. **I. Andreadou**\*, E. K. Iliodromitis, M. Koufaki, D. Farmakis, A. Tsotinis, D. Th. Kremastinos. Alternative pharmacological interventions that limit myocardial infarction. **Curr Med Chem**, 15: 1304-1313, 2008. (IF: 3.455) (Citations 19)
60. P. Georgiadou, E.K. Iliodromitis, F. Kolokathis, M Mavroidis, **I. Andreadou**, M. Demopoulou, Ch. Varounis, Y. Capetanaki, H. Boudoulas, D.Th. Kremastinos. Plasma levels of osteopontin before and 24 hours after percutaneous coronary intervention. **Expert Opinion on Therapeutic Targets**, 12: 1477-1480, 2008. (IF: 4.798) (Citations 8)
61. E. K. Iliodromitis, I. A. Paraskevaïdis, K. Fountoulaki, D. Farmakis, **I. Andreadou**, A. Antoniadis, I. Ikonomidis, D. Leftheriotis, D. T. Kremastinos. Staccato reperfusion prevents reperfusion injury in patients undergoing coronary angioplasty: A one-year follow-up pilot study. **Atherosclerosis**, 204: 497-502, 2009. (IF: 3.942) (Citations 10)
62. **I. Andreadou**, M. Papaefthimiou, A. Zira, M. Constantinou, F. Sigala, A.-L. Skaltsounis, A. Tsantili-Kakoulidou, E.K. Iliodromitis, D.Th. Kremastinos, E.Mikros. Metabonomic identification of novel biomarkers in doxorubicin cardiotoxicity and protective effect of the natural antioxidant oleuropein. **NMR Biomed**, 22: 585-92, 2009. (IF: 2.983) (Citations 50)

63. J. T. Parissis, K. Kourea, **I. Andreadou\***, I. Ikonomidis, S. Markantonis, K. Ioannidis, I. Paraskevaïdis, E. Iliodromitis, G. Filippatos, D. Th Kremastinos. Effects of darbepoetin-alpha on plasma mediators of oxidative and nitrosative stress in anemic patients with chronic heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. **Am J Cardiol**, 103: 1134-113, 2009. (IF: 3.154) (Citations 25)
64. E. Avgerinos, G. Kostopanagiotou, C. Costopanagiotou, N. Kopanakis, **I. Andreadou**, M. Lekka, G. Nakos, V. Smyrniotis. Intestinal preconditioning ameliorates ischemia-reperfusion induced acute lung injury in rats: an experimental study. **J Surg Res**, 160: 294-301, 2010. (IF: 2.198) (Citations 15)
65. V. Panteleon, I. K. Kostakis, P. Marakos, N. Pouli, **I. Andreadou**. Synthesis of some new sSpiropyranquinolines and evaluation of their free radical scavenging activity. **Chem Pharm Bull**, 57(5): 446-452, 2009. (IF: 1.228) (Citations 2)
66. I. Ikonomidis, S. Tzortzis, J. Lekakis, I. Paraskevaïdis, **I. Andreadou**, M. Nikolaou, T. Kaplanoglou, P. Katsimbri, G. Skarantavos, P. Soucacos, D.T. Kremastinos. Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. **Heart**, 95: 1502-7, 2009. (IF: 5.693) (Citations 30)
67. **I. Andreadou\***, E. K. Iliodromitis, D. Farmakis, D Th. Kremastinos. To prevent, protect and save the ischemic heart: antioxidants revisited. **Expert Opinion on Therapeutic Targets**, 13: 945-956, 2009. (IF: 4.798) (Citations 61).
68. E.K. Iliodromitis, **I. Andreadou\***, E. Prokovas, A. Zoga, D. Farmakis, T. Fotopoulou, K. Ioannidis, I.A. Paraskevaïdis, D.Th. Kremastinos. Simvastatin in contrast to postconditioning reduces infarct size in hyperlipidemic rabbits: possible role of oxidative/nitrosative stress. **Basic Res Cardiol**, 105:193-203, 2010. (IF: 6.008) (Citations 54)
69. Arkadopoulos N, Kalimeris K, Papalois A, Nastos C, Papoutsidakis N, Defterevos G, Zarkadis IK, Mikrou A, Pafiti A, **Andreadou I**, Kostopanagiotou G, Smyrniotis V. Treatment with bioartificial liver improves lung injury in a swine model of partial hepatectomy and ischemia/reperfusion. **Int J Artif Organs**, 33:105-13, 2010 (IF: 1.005) (Citations 2)
70. F. Sigala, A. Kotsinas, K. Filis, S. Markantonis, E. K. Iliodromitis, V. G Gorgoulis, **I. Andreadou\***. Oxidized LDL in human carotid plaques is related to symptomatic carotid disease and lesion instability. **J Vasc Surg**, 52: 704-713, 2010. (IF: 3.454) (Citations 33)
71. K Kalimeris, C Nastos, N Papoutsidakis, MN Xanthopoulou, G Deftervos, A Tympa, A Pafiti, **I Andreadou**, G Kostopanagiotou, V Smyrniotis, N Arkadopoulos. Iron chelation prevents lung injury after major hepatectomy. **Hepatol Res**, 40: 841-850, 2010. (IF: 2.208) (Citations 9)

72. I. Ikonomidis, E. K. Iliodromitis, S. Tzortzis, A. Antoniadis, I. Paraskevaidis, **I. Andreadou**, K. Fountoulaki, D. Farmakis, D. T. Kremastinos, M. Anastasiou-Nana. Staccato reperfusion improves myocardial microcirculatory function and long-term left ventricular remodelling: A randomized contrast echocardiography study. **Heart**, 96: 1898-1903, 2010. (IF: 5.693) (Citations 14)
73. F. Tsopelas, M. Ochsenkühn-Petropoulou, N. Zikos, E. Spyropoulou, **I. Andreadou**, A. Tsantili-Kakoulidou. Electrochemical study of some non-steroidal anti-inflammatory drugs: solvent effect and antioxidant activity. **J Solid State Electrochem**, 15: 1099-1108, 2011. (IF: 2.327) (Citations 8)
74. C.A. Michalakeas, J.T. Parissis, A. Douzenis, M. Nikolaou, C. Varounis, **I. Andreadou**, N. Antonellos, S. Markantonis-Kiroudis, I. Paraskevaidis, I. Ikonomidis, E. Lykouras, D. Kremastinos. Effects of sertraline on circulating markers of oxidative stress in depressed patients with chronic heart failure: a pilot study. **J Card Fail**, 17: 748-754, 2011. (IF: 3.259) (Citations 19)
75. **I. Andreadou\***, E.K. Iliodromitis, V. Souridis, E. Prokovas, S. Kostidis, A. Zoga, N. Dages, A. Tsantili-Kakoulidou, D.T. Kremastinos, E. Mikros, M. Anastasiou-Nana. Investigating the effect of antioxidant treatment on the protective effect of preconditioning in anesthetized rabbits. **J Cardiovasc Pharmacol**, 58: 609-616, 2011. (IF: 2.462) (Citations 1)
76. I. Ikonomidis, S. Tzortzis, J. Lekakis, I. Paraskevaidis, P. Dasou, J. Parissis, M. Nikolaou, S.L. Markantonis, P. Katsimbri, G. Skarantavos, **I. Andreadou\***, M. Anastasiou-Nana. Association of soluble apoptotic markers with impaired left ventricular deformation in patients with rheumatoid arthritis. Effects of inhibition of interleukin-1 activity by anakinra. **Thromb Haemost**, 106: 959-967, 2011. (IF: 5.255) (Citations 9)
77. D.J. Hausenloy, E.K. Iliodromitis, **I. Andreadou**, A. Papalois, G. Gritsopoulos, M. Anastasiou-Nana, D.T. Kremastinos, D.M. Yellon. Investigating the Signal Transduction Pathways Underlying Remote Ischemic Conditioning in the Porcine Heart. **Cardiovasc Drugs Ther**, 26(2):87-93, 2012. (IF: 3.189) (Citations 43)
78. N. Arkadopoulos, C. Nastos, G. Defterevos, K. Kalimeris, N. Papoutsidakis, **I. Andreadou**, T. Nomikos, A. Pafiti, G. Fragulidis, E. Economou, P. Varsos, G. Kostopanagiotou, V. Smyrniotis. Pancreatic injury after major hepatectomy: a study in a porcine model. **Surg Today**, 42(4):368-375, 2012. (IF: 1.329) (Citations 3)
79. D. Farmakis, **I. Andreadou**, A. Aessopos. High-sensitivity troponin assays: ready for prime-time use as surrogates of subclinical myocardial injury? **J Am Coll Cardiol**, 60(2):166, 2012. (IF: 17.759) (Citations 4)
80. **I. Andreadou\***, D. Farmakis, E. Prokovas, F. Sigala, A. Zoga, K. Spyridaki, A. Papalois, A. Papapetropoulos, M. Anastasiou-Nana, D.Th. Kremastinos, E.K. Iliodromitis. Short-term statin administration in hypercholesterolemic rabbits

- resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase and nitro-oxidative stress. **Cardiovasc Res**, 94: 501-509, 2012. (IF: 5.465) (Citations 35)
81. M. Koufaki, T. Fotopoulou, E.K. Iliodromitis, S-I. Bibli, A. Zoga, D.Th. Kremastinos, **I. Andreadou**. Discovery of 6-[4-(6-nitroxyhexanoyl)piperazin-1-yl]-9H-purine, as pharmacological post-conditioning agent. **Bioorg Med Chem**, 20(19): 5946-5956, 2012. (IF: 2.923) (Citations 1)
  82. E. Demerouti, **I. Andreadou**\*, I.-K. Aggeli, D. Farmakis, A. Zoga, C. Gaitanaki, I. Beis, M. Anastasiou-Nana, D.Th. Kremastinos, E.K. Iliodromitis. Ovariectomy reinstates the infarct size-limiting effect of postconditioning in female rabbits. **Cell Biochem Biophys**, 65(3):373-80, 2013. (IF: 1.627) (Citations 4).
  83. A. Zira, S. Kostidis, S. Theocharis, F. Sigala, S.B. Engelsen, **I. Andreadou**, E. Mikros. <sup>1</sup>H NMR-based metabonomics approach in a rat model of acute liver injury and regeneration induced by CCl<sub>4</sub> administration. **Toxicology**, 303:115-24, 2013. (IF: 3.817) (Citations 26).
  84. K. Iliodromitis, D. Farmakis, **I. Andreadou**\*, A. Zoga, S-I. Bibli, T. Manolaki, N. Dages, E.K. Iliodromitis, M. Anastasiou-Nana, D.Th. Kremastinos. Various models of cardiac conditioning in single or sequential periods of ischemia: comparative effects on infarct size and intracellular signalling. **Int J Cardiol**, 168(2):1336-41, 2013. (IF: 4.638) (Citations 1).
  85. G. Hatzis, P. Ziakas, N. Kavantzas, A. Triantafyllou, P. Sigalas, **I. Andreadou**, K. Ioannidis, S. Chatzis, K. Filis, A. Papalampros, F. Sigala. Melatonin attenuates high fat diet-induced fatty liver disease in rats **World J Hepatol**, 5(4): 160-169, 2013. (Citations 19)
  86. S-I. Bibli, **I. Andreadou**\*, E. Lazaris, A. Zoga, V. Varnavas, C.C. Andreou, N. Dages, E.K. Iliodromitis, Z.S. Kyriakides. Myocardial protection provided by chronic skeletal muscle ischemia is not further enhanced by ischemic pre- or post-conditioning: comparative effects on intracellular signalling. **J Cardiovasc Pharmacol Ther**, 19(2):220-7, 2014. (IF: 2.538) (Citations 3).
  87. M. Svobodova, **I. Andreadou**, A-L. Skaltsounis, J. Kopecky, P. Flachs. Oleuropein as an inhibitor of peroxisome proliferator-activated receptor gamma. **Genes & Nutrition**, 9(1):376, 2014. (IF: 2.398) (Citations 3)
  88. **I. Andreadou**\*, E. Mikros, K. Ioannidis, F. Sigala, K. Naka, S. Kostidis, D. Farmakis, R. Tenta, N. Kavantzas, S-I. Bibli, E. Gikas, L. Skaltsounis, D.Th. Kremastinos, E.K. Iliodromitis. Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. **J Mol Cell Cardiol**, 69:4-16, 2014. (IF: 4.874) (Citations 22)
  89. S-I. Bibli, E.K. Iliodromitis, C. Lambertucci, A. Zoga, N. Lougiakis, N. Dages, R. Volpini, D. Dal Ben, D.Th. Kremastinos, A. Tsantili-Kakoulidou, G. Cristalli, **I. Andreadou**\*. Pharmacological postconditioning of the rabbit heart

- with non-selective, A<sub>1</sub>, A<sub>2A</sub> and A<sub>3</sub> adenosine receptor agonists. **J Pharm Pharmacol**, 66(8):1140-1149, 2014. (IF: 2.363) (Citations 5).
90. E.K. Iliodromitis, **I. Andreadou**, C. Iliodromitis, N. Dages. Ischemic and postischemic conditioning of the myocardium in clinical practice: Challenges, expectations and obstacles. **Cardiology**, 129(2):117-125, 2014. (IF: 1.994) (Citations 6).
91. I. Ikonomidis, S. Tzortzis, **I. Andreadou**, I. Paraskevaidis, Katseli C., P. Katsimbri, J. Parissis, M. Anastasiou-Nana, J. Lekakis. Increased benefit of interleukin 1 inhibition on vascular function, myocardial deformation, and twisting in patients with coronary artery disease and coexisting rheumatoid arthritis. **Circulation: Cardiovascular Imaging**, 7(4):619-628, 2014. (IF: 5.744) (Citations 23)
92. **I. Andreadou**\*, E.K. Iliodromitis, T. Rassaf, R. Schulz, A. Papapetropoulos, P. Ferdinandy. The role of gasotransmitters NO, H<sub>2</sub>S, CO in myocardial ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. **Brit J Pharmacol**, 172: 1587-1606, 2015. (IF: 5.259) (Citations 38)
93. I. Ikonomidis, G. Makavos, E. Papadavid, M. Varoudi, **I. Andreadou**, K. Gravanis, K. Theodoropoulos, Pavlidis G., Triantafyllidi H., Parissis J., Paraskevaidis I., Rigopoulos D., Lekakis J. Similarities in coronary function and myocardial deformation between psoriasis and coronary artery disease: the role of oxidative stress and inflammation. **Can J Cardiol**, 31(3):287-295, 2015. (IF: 3.112) (Citations 10).
94. **Andreadou I.**\*, Bibli S-I., Mastromanolis E., Zoga A., Efentakis P., Papaioannou N., Farmakis D., Kremastinos DTh., Iliodromitis EK.. Transient carotid ischemia as a remote conditioning stimulus on myocardial infarction size in anesthetized rabbits: insights into the intracellular signalling. **Int J Cardiol**, 184C:140-151, 2015. (IF: 4.638) (Citations 2).
95. van der Stelt I., Hoek-van den Hil E.F., Swarts H.J.M., Vervoort J.J.M., Hoving L., Skaltsounis L., Lemonakis N., **Andreadou I.**, van Schothorst E.M., Keijer J.. Nutraceutical oleuropein supplementation prevents high fat diet-induced adiposity in mice. **J Function Food**, 14:702–715, 2015. (IF: 3.973) (Citations 5).
96. Bibli S-I., **Andreadou I\***., Chatzianastasiou A; Tzimas C, Sanoudou D., Kranias E., Brouckaert P., Coletta C., Szabo C., Kremastinos DTh., Iliodromitis EK., Papapetropoulos A. Cardioprotection by H<sub>2</sub>S engages a cGMP-dependent protein kinase G/phospholamban pathway. **Cardiovasc Res**, 106(3):432-42, 2015. (IF: 5.465) (Citations 9).
97. **Andreadou I.\***, Farmakis D., Iliodromitis E.K. Ligands involved in conditioning may enhance the protection afforded by remote ischemia and reperfusion **Int J Cardiol**, 190:273-274, 2015. (IF: 4.638) (Citations 1).

98. **Andreadou I\***, Benaki D., Efentakis P., Bibli S-I., Milioni A-I., Papachristodoulou A., Zoga A., Skaltsounis A-L., Mikros E., Iliodromitis E K.. The natural olive constituent oleuropein induces nutritional cardioprotection in normal and cholesterol fed rabbits: comparison with preconditioning. **Planta Medica**, 81:655-63, 2015. (IF: 1.99) (Citations 2).
99. Iliodromitis E.K., Cohen M.V., Dages N., **Andreadou I**, Kremastinos D.Th., Downey J.M. What is wrong with cardiac conditioning? We may be shooting at moving targets. **J Cardiovas Pharmacol Ther**, 20:357-69, 2015. (IF: 2.538) (Citations 5).
100. Efentakis P., Iliodromitis E.K., Mikros E., Papachristodoulou A., Dages N., Skaltsounis A-L., **Andreadou I\***. Effects of the olive tree leaf constituents on myocardial oxidative damage and atherosclerosis. **Planta Medica**, 81:648-54, 2015. (IF: 1.99) (Citations 6).
101. **Andreadou I**, Iliodromitis EK, Szabo C, Papapetropoulos A. Hydrogen sulfide and PKG in ischemia–reperfusion injury: sources, signaling, accelerators and brakes. **Basic Res Cardiol**, 110:52, 2015. (IF: 6.008) (Citations 3).
102. N. Lougiakis, A. Papapetropoulos, E. Gikas, S. Toumpas, P. Efentakis, R. Wedmann, A. Zoga, Z. Zhou, E. K. Iliodromitis, A.-L. Skaltsounis, M. R. Filipovic, N. Pouli, P. Marakos, **I. Andreadou\***. Synthesis and pharmacological evaluation of novel adenine-hydrogen sulfide slow release hybrids designed as multi-target cardioprotective agents. **J Med Chem**, 59(5):1776-90, 2016. (IF: 5.589).
103. **I. Andreadou\***, S. Mitakou, S. Paraschos, P. Efentakis, P. Magiatis, L. Kaklamanis, M. Halabalaki, L. Skaltsounis, E.K. Iliodromitis. “*Pistacia lentiscus* L.” reduces the infarct size in normal fed anesthetized rabbits and possess antiatheromatic and hypolipidemic activity in cholesterol fed rabbits. **Phytomedicine**, 23: 1220-1226, 2016. (IF: 2.937) (Citations 1).
104. Chatzianastasiou A, Bibli SI, **Andreadou I**, Efentakis P, Kaludercic N, Wood ME, Whiteman M, Di Lisa F, Daiber A, Manolopoulos VG, Szabo C, Papapetropoulos A. Cardioprotection by H<sub>2</sub>S donors: nitric oxide-dependent and -independent mechanisms. **J Pharmacol Exp Ther**, 358(3):431-40, 2016. (IF: 3.76) (Citations 1).
105. Efentakis P, **Andreadou I\***, Bibli S-I, Vasileiou S, Dages N, Zoga A, Lougiakis N, Kremastinos DTh, Iliodromitis EK. Ranolazine triggers pharmacological preconditioning and postconditioning in anesthetized rabbits through activation of RISK pathway. **Eur J Pharmacol**, 789:431-438, 2016. (IF: 2.73).
106. Bibli SI, **Andreadou I**, Glynos C, Chatzianastasiou A, Toumpanakis D, Zakyntinos SG, Vassilakopoulos T, Iliodromitis EK, Papapetropoulos A. Exposure to cigarette smoke abrogates the beneficial effect of ischemic postconditioning. **Am J Physiol Heart Circ Physiol**, in press. (IF: 3.324).

## **CHAPTERS IN BOOKS**

### **1. New Ischemic syndromes**

*Cardiology*, Dimitrios Th. Kremastinos, Ed. Pashalidies, 2009, p. 1433-1448.  
Efstathios Iliodromitis, **Ioanna Andreadou**, Agathi-Roza Vrettou.

### **2. The Use of Oleuropein on Myocardium**

*Olives and Olive Oil in Health and Disease Prevention*, 2010, Pages 1313-1320  
**Ioanna Andreadou**, Efstathios K. Iliodromitis, Emmanuel Mikros, Alexios-Leandros Skaltsounis, Dimitrios Th. Kremastinos

**3. Pre- Peri- Post-Conditioning the Ischemic Myocardium: Challenges, Confounders and Expectations.** *Introduction to Translational Cardiovascular Research 2015*, pp 541-552 Efstathios K. Iliodromitis, **Ioanna Andreadou**, Nikolaos Dages, Dimitrios T. Kremastinos.

## **PUBLICATIOIOS OF CLINICAL TRIALS**

1. PREAMI: Perindopril and remodeling in elderly with acute myocardial infarction: study rationale and design. The PREAMI investigators. **Cardiovascular Drugs and Therapy**, 14: 671-679, 2000.
2. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study). **The Lancet**, 362: 782-788, 2003.

## **REVIEW PAPERS IN GREEK JOURNALS**

1. **I. Andreadou\***, E. Iliodromitis. Oxidative stress and cardiovascular disease. **Farmakeftiki**, 16 (IV): 101-108, 2003.
2. E. I. Bavavea, E. Avgeropoulou, **I. Andreadou\***. Pulmonary arterial hypertension: pharmaceutical treatment. **Farmakeftiki**, 22(III): 73-82, 2009.
3. D.E. Andreou, **I. Andreadou\***. Atherosclerosis: an inflammatory disease. **Farmakeftiki**, 22(III): 83-96, 2009.
4. E.-S. Gavriil E. Karalis, **I. Andreadou**. Clopidogrel: Factors that affect its action. **Pharmakeftiki**, 25(1): 1-15, 2013.
5. F.Tsouki, **I. Andreadou**. Overview of the newer hypolipidaemic agents. **Pharmakeftiki** 27( 1-2): 1-14, 2015.

## **CONFERENCES PRESENTATIONS**

99 CONFERENCES PUBLICATIONS (ISI WEB SCI)

125 presentations in Greek and International Conferences.

12 CONFERENCES AWARDS.

## **BIBLIOMETRIC DATA**

Total number of publications: **106**

Impact Factor (IF): **373.989/102**

Median IF: **3.67**

IF, 1<sup>st</sup> and/or 2<sup>nd</sup> author and/or correspondence author: **219.407/58= 3.78**

**Median IF: 38 corresponding author papers, 146.234/38= 3.85**

HF (total citations): **29**

**HF (excluding self-citations): 27**